REC 0545
Alternative Names: Maapliv; REC-0545Latest Information Update: 19 May 2026
At a glance
- Originator Assistance Publique Hopitaux de Paris; Recordati
- Class Amino acids
- Mechanism of Action Amino acid replacements
-
Orphan Drug Status
Yes - Maple syrup urine disease
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Registered Maple syrup urine disease
- Discontinued Genitourinary disorders; Overactive bladder
Most Recent Events
- 28 Jul 2025 Registered for Maple syrup urine disease in European Union, Norway, Iceland, Liechtenstein (IV)
- 31 Dec 2023 Clinical trials in Maple syrup urine disease (unspecified route) before December 2023 (Recordati pipeline, February 2024)
- 31 Dec 2023 Recordati announces intention to file regulatory application for Maple syrup urine disease in 2023 (Recordati pipeline, February 2024)